Identifying a novel locus for psoriatic arthritis

被引:14
|
作者
Budu-Aggrey, Ashley [1 ,2 ,3 ]
Bowes, John [1 ]
Barton, Anne [1 ,2 ,3 ,4 ]
机构
[1] Univ Manchester, Arthrit Res UK Ctr Genet & Genom, Manchester M13 9PT, Lancs, England
[2] Cent Manchester Fdn Trust, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci, Manchester M13 9PT, Lancs, England
[4] Cent Manchester Fdn Trust, NIHR Manchester Biomed Res Ctr, Kellgren Ctr Rheumatol, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Psoriatic arthritis; psoriasis; specific risk loci; Immunochip; functional characterization; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; METHOTREXATE; VARIANTS; EFFICACY; PHASE-3; PTPN22;
D O I
10.1093/rheumatology/kev273
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A number of studies have identified genetic risk loci for PsA, the majority of which also confer risk for psoriasis. The stronger heritability of PsA in comparison with psoriasis suggests that there should be risk loci that are specific for PsA. Identifying such loci could potentially inform therapy development to provide more effective treatments for PsA patients, especially with a considerable proportion being non-responsive to current therapies. Evidence of a PsA-specific locus has been previously found at HLA-B27 within the MHC region. A recent study has provided evidence of non-HLA risk loci that are specific for PsA at IL23R, PTPN22 and on chromosome 5q31. Functional characterization of these loci will provide further understanding of the pathways underlying PsA, and enable us to apply genetic findings for patient benefit.
引用
收藏
页码:25 / 32
页数:8
相关论文
共 50 条
  • [1] Management of psoriatic arthritis
    Sharma, Aman
    Dogra, Sunil
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2010, 76 (06): : 645 - 651
  • [2] Psoriatic arthritis - what the dermatologist needs to know
    Laws, P.
    Barton, A.
    Warren, R. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (11) : 1270 - 1277
  • [3] Biologic Therapy for Psoriatic Arthritis
    Mease, Philip J.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (04) : 723 - +
  • [4] Emerging drugs for psoriatic arthritis
    Olivieri, Ignazio
    D'Angelo, Salvatore
    Palazzi, Carlo
    Lubrano, Ennio
    Leccese, Pietro
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (03) : 399 - 414
  • [5] New biologics for psoriasis and psoriatic arthritis
    Rozenblit, Mariya
    Lebwohl, Mark
    DERMATOLOGIC THERAPY, 2009, 22 (01) : 56 - 60
  • [6] Psoriatic arthritis assessment and treatment update
    Mease, Philip J.
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (04) : 348 - 355
  • [7] New therapies for psoriasis and psoriatic arthritis
    Ritchlin, Christopher T.
    Krueger, James G.
    CURRENT OPINION IN RHEUMATOLOGY, 2016, 28 (03) : 204 - 210
  • [8] Novel approaches to biological therapy for psoriatic arthritis
    Boyd, Tristan
    Kavanaugh, Arthur
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 173 - 186
  • [9] Novel Therapeutic Approaches and Treatment Targets for Psoriatic Arthritis
    Benfaremo, Devis
    Paci, Valentino
    Luchetti, Michele Maria
    Gabrielli, Armando
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2021, 22 (01) : 85 - 98
  • [10] Targeting cytokines in psoriatic arthritis
    Neurath, Laura
    Sticherling, Michael
    Schett, Georg
    Fagni, Filippo
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 78 : 1 - 13